Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenxbio (RGNX) EBITDA Margin (2016 - 2025)

Regenxbio has reported EBITDA Margin over the past 12 years, most recently at 221.46% for Q4 2025.

  • Quarterly results put EBITDA Margin at 221.46% for Q4 2025, up 2057.0% from a year ago — trailing twelve months through Dec 2025 was 113.72% (up 15439.0% YoY), and the annual figure for FY2025 was 113.72%, up 15439.0%.
  • EBITDA Margin for Q4 2025 was 221.46% at Regenxbio, down from 207.99% in the prior quarter.
  • Over the last five years, EBITDA Margin for RGNX hit a ceiling of 73.43% in Q4 2021 and a floor of 397.71% in Q1 2024.
  • Median EBITDA Margin over the past 5 years was 240.69% (2024), compared with a mean of 237.81%.
  • Biggest five-year swings in EBITDA Margin: tumbled -25553bps in 2022 and later skyrocketed 40452bps in 2025.
  • Regenxbio's EBITDA Margin stood at 73.43% in 2021, then crashed by -348bps to 182.1% in 2022, then plummeted by -48bps to 269.68% in 2023, then increased by 10bps to 242.03% in 2024, then grew by 9bps to 221.46% in 2025.
  • The last three reported values for EBITDA Margin were 221.46% (Q4 2025), 207.99% (Q3 2025), and 331.75% (Q2 2025) per Business Quant data.